6 stories mentioning CRLUpdated 46m ago
Every FINWIRES story that references CRL, newest first.
Charles River Laboratories (CRL) shares rose over 1% on Wednesday after Morgan Stanley upgraded the stock to overweight from equal weight, and adjusted the price target to $220 from $185Trading volume stood at over 464,600 shares compared with a daily average of about 855,500.Price: $186.68, Change: $+1.89, Percent Change: +1.02%
Charles River Laboratories International (CRL) has an average rating of overweight and mean price target of $220.29, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Charles River Laboratories (CRL) has the potential to outperform expectations in the second half of 2026, RBC Capital Markets analysts said in a Thursday note.Analysts said that the company's "Pathways to Purpose" strategy is positioning it to capitalize on improving biotech funding and pharma investment in research and development.RBC said that the company sees various opportunities, including in China, New Alternative Methods, and organic market share gains from a recent competitor's bankruptcy."We expect strong biopharma funding to continue in 2026 which combined with healthy cash runways should manifest in accelerated preclinical R&D spending growth in 2026 and into 2027," analysts said.RBC has an outperform rating and a $215 price target on the stock.Price: $184.94, Change: $-0.85, Percent Change: -0.46%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Charles River (CRL) delivered Q1 2026 revenue of $995.8M (+1.2% Y/Y, -1.5% organic), beating the $994M consensus, while adjusted EPS of $2.06 (-12.0% Y/Y) exceeded the $1.94 consensus view. Research Models and Services faced headwinds with organic revenue declining 5.5% to $208.4M and operating margin compressing 240 bps to 24.7%, while Discovery and Safety Assessment revenue was flat at $596.9M with margin pressure of 290 bps to 21.0%. CRL successfully completed strategic divestitures of its CDMO and Cell Solutions businesses on May 6, with additional European Discovery Services site sales expected this month. Management maintained yearly guidance for organic sales growth and adjusted EPS despite less favorable FX expectations. Manufacturing Solutions showed resilience with revenue of $190.5M (+2.9% organic) and operating margin improving 280 bps to 25.9% from restructuring cost savings. The company returned $200M to shareholders through repurchases, leaving $800M remaining in authorization.
Charles River Laboratories International's (CRL) is positioned as the "leading" contract research organization, or CRO, for the acceleration of preclinical research and development into 2027, RBC Capital Markets said in a Monday note.RBC said improving macro conditions appear to be setting up an inflection in research and development spending, potentially starting in H2 and then accelerating through 2027. This expected increase in spending should benefit drive outsourcing to CROs and benefit Charles River Laboratories, the brokerage noted.Charles River Laboratories could also see an opportunity in the ongoing evolution of new alternative methods or NAMs, depending on the company's adoption of NAMS, RBC said.RBC initiated coverage on Charles River Laboratories International with an outperform rating and $215 price target.Price: $181.87, Change: $+3.53, Percent Change: +1.98%
Charles River Laboratories International (CRL) has an average rating of overweight and mean price target of $203.93, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
